Τίτλος:
Lipid-associated sialoprotein in the cerebrospinal fluid - Association
with brain malignancies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
BACKGROUND. Changes in the glycosylation process by tumor cells result
in larger amounts of sialoproteins on their surface compared with normal
cells. Sialoproteins then are released into the surrounding environment
primarily by shedding or cell lysis. In the current study, the authors
attempted to evaluate whether lipid-associated sialoprotein (LSP) in the
cerebrospinal fluid (CSF) can distinguish patients with primary and
metastatic brain tumors from those without brain tumors as well as
determine response to treatment.
METHODS. CSF samples were obtained from a tissue bank. The concentration
of LSP was determined after chloroform:methanol extraction followed by
protein precipitation. One-way analysis of variance end Scheffe pairwise
comparisons were used for statistical analysis.
RESULTS. The CSF of neurologically normal controls, patients with a
normal leukocyte count (less than or equal to 5/muL), and patients with
various neurologic disorders or systemic tumors without central nervous
system (CNS) malignancies contained similar levels of LSP. The CSF from
patients with a normal leukocyte count and newly diagnosed primary or
metastatic brain tumors contained on average 3.7-fold higher levels of
LSP compared with CSF from patients without CNS tumors (P = 0.0001). The
CSF from patients with brain tumors with progressive disease not
responding to treatment contained high levels of LSP comparable to the
levels found in newly diagnosed patients. The CSF from
treatment-responsive patients contained decreased levels of LSP similar
to that found in control patients.
CONCLUSIONS. The LSP in CSF may be a useful marker with which to
determine the presence of intracranial malignancies and assess response
to treatment. (C) 2001 American Cancer Society.
Συγγραφείς:
Katopodis, N
Glantz, MJ
Kim, L
Dafni, U
Wu, JK and
Perides, G
Εκδότης:
John Wiley & Sons, Inc
Λέξεις-κλειδιά:
brain tumors; cerebrospinal fluid; central nervous system metastases;
tumor marker; sialic acid
DOI:
10.1002/1097-0142(20010815)92:4<856::AID-CNCR1393>3.0.CO;2-9
